Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial.

被引：0
|
作者：
Glennatempo, Patrizia
Mariani, Luigi
Nicolai, Nicola
Fare, Elena
Raggi, Daniele
Maronglu, Manuals
Plva, Luigi
Blasonl, Davide
Catanzaro, Mario
Torelli, Tullio
Stagni, Silvia
Maffezzini, Massimo
Togliardi, Elena
Salvioni, Roberto
De Braud, Filippo G.
Gianni, Alessandro M.
Necchi, Andrea
机构：
[1] Fdn IRCCS Ist Nazl Turnori, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Unit Clin Epidemiol & Trial Org, Milan, Italy
[3] Natl Canc Istitute Milan, Milan, Italy
[4] Univ Milan, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PAZOPANIB IN CHEMORESISTANT PATIENTS WITH GERM CELL TUMORS (GCT): UPDATED RESULTS OF THE OPEN-LABEL, SINGLE-GROUP, PHASE 2 PAZOTEST-01 TRIAL
    Necchi, Andrea
    Giannaternpo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo
    Gianni, Alessandro
    [J]. ANTICANCER RESEARCH, 2014, 34 (05) : 2661 - 2662
  • [2] Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).
    Necchi, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Crippa, Flavio
    Mariani, Luigi
    Salvioni, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial
    Giannatempo, Patrizia
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Crestani, Alessandro
    Togliardi, Elena
    Salvioni, Roberto
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
    Necchi, Andrea
    Lo Vullo, Salvatore
    Giannatempo, Patrizia
    Raggi, Daniele
    Calareso, Giuseppina
    Togliardi, Elena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [5] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [6] An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
    Necchi, Andrea
    Magazzu, Domenico
    Anichini, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Nicolai, Nicola
    Colecchia, Maurizio
    Paolini, Biagio
    Coradeschi, Elisa
    Tassi, Elena
    Grazia, Giulia
    Mortarini, Roberta
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Salvioni, Roberto
    Gianni, Alessandro M.
    Valagussa, Pinuccia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] An open-label, single-group, phase 2 study of Brentuximab Vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): results at the end of first stage (FM12GCT01)
    Necchi, A.
    Magazzu, D.
    Anichini, A.
    Raggi, D.
    Giannatempo, P.
    Colecchia, M.
    Coradeschi, E.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Salvioni, R.
    Valagussa, P.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S56 - S56
  • [8] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    Kaufman, Howard L.
    Russell, Jeffery
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    [J]. LANCET ONCOLOGY, 2016, 17 (10): : 1374 - 1385
  • [9] Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
    Necchi, Andrea
    Mariani, Luigi
    Zaffaroni, Nadia
    Schwartz, Lawrence H.
    Giannatempo, Patrizia
    Crippa, Flavio
    Morosi, Carlo
    Lanocita, Rodolfo
    Sava, Teodoro
    Ortega, Cinzia
    Messina, Caterina
    Sacco, Cosimo
    Pennati, Marzia
    Daidone, Maria G.
    Nicolai, Nicola
    De Braud, Filippo
    Gianni, Alessandro M.
    Salvioni, Roberto
    [J]. LANCET ONCOLOGY, 2012, 13 (08): : 810 - 816
  • [10] Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Gurioli, Giorgia
    Pisano, Carmela
    Basso, Umberto
    Lolli, Cristian
    Petracci, Elisabetta
    Casadei, Chiara
    Cecere, Sabrina Chiara
    Attademo, Laura
    Clemente, Alberto
    Zampiga, Valentina
    Galla, Valentina
    Cangini, Ilaria
    Di Napoli, Marilena
    Valmorri, Linda
    Pignata, Sandro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345